| Basics |
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
|
| IPO Date: |
December 22, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$11.42B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.88 | 1.98%
|
| Avg Daily Range (30 D): |
$0.64 | 0.98%
|
| Avg Daily Range (90 D): |
$0.78 | 1.59%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.17M |
| Avg Daily Volume (30 D): |
1.65M |
| Avg Daily Volume (90 D): |
1.94M |
| Trade Size |
| Avg Trade Size (Sh.): |
84 |
| Avg Trade Size (Sh.) (30 D): |
58 |
| Avg Trade Size (Sh.) (90 D): |
64 |
| Institutional Trades |
| Total Inst.Trades: |
11,043 |
| Avg Inst. Trade: |
$2.64M |
| Avg Inst. Trade (30 D): |
$5.14M |
| Avg Inst. Trade (90 D): |
$3.93M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.2M |
| Avg Closing Trade (30 D): |
$20.78M |
| Avg Closing Trade (90 D): |
$15.8M |
| Avg Closing Volume: |
140.89K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$.78
|
$-.93
|
$-.66
|
|
Diluted EPS
|
$.7
|
$-.93
|
$-.66
|
|
Revenue
|
$ 452.05M
|
$ 131.61M
|
$ 226.58M
|
|
Gross Profit
|
$ 447.9M
|
$ 130.15M
|
$ 222.75M
|
|
Net Income / Loss
|
$ 123.55M
|
$ -146.94M
|
$ -104.35M
|
|
Operating Income / Loss
|
$ 139.82M
|
$ -146.86M
|
$ -110.82M
|
|
Cost of Revenue
|
$ 4.15M
|
$ 1.46M
|
$ 3.83M
|
|
Net Cash Flow
|
$ 32.52M
|
$ 21.88M
|
$ -92.04M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
